Breaking News Headlines Today

News from biotuesdays.com

See all of biotuesdays.com’s headline news. Compare how the top news stories are covered by left-wing and right-wing news sources.

We’ve discovered 93 headlines written by biotuesdays.com during the past 3 months.

biotuesdays.com’s media bias is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Is biotuesdays.com credible or reliable? Our Factuality score answers both of those questions. When it comes to biotuesdays.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about biotuesdays.com

Where is biotuesdays.com located?biotuesdays.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top biotuesdays.com News

Parkinson's Disease · Montreal

Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada

83% Left coverage: 6 sources

MONTREAL, July 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company,...See the Story

United States · United States

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Coverage: 2 sources

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 23, 2025-See the Story

Medical · Singapore

Cuprina Appoints Dr. Ronald Sherman, Leader in Maggot Debridement Therapy, as Medical and ...

100% Center coverage: 1 sources

SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“CUPR” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well…See the Story

Bioxytran disrupting infectious disease and inflammation with carbohydrate-based therapeutics - BioTuesdays

Open the article to view the coverage from biotuesdays.com Read Article

VVT Med completes RTO of V.V.T. Med and Exiteam Acquisition - BioTuesdays

VVT Med (TSXV: DXI.H) (formerly DXI Capital) announced that it has completed its previously announced acquisition of all of the outstanding securities of V.V.T. Med (VVT) and Exiteam Acquisition (EAC), according to the terms of a definitive agreement dated September 30, 2024. VVT stated further details regarding the transaction are available in the company’s filing statement dated May 15, 2025, and its news releases dated May 21, 2025, June 30,…Canada · Canada Read Article

Jupiter spotlights critical advancement of JOTROL v conventional resveratrol - BioTuesdays

Jupiter Neurosciences (NASDAQ: JUNS) has highlighted the critical advancement of its proprietary resveratrol platform, JOTROL, compared to conventional resveratrol formulations, citing breakthrough bioavailability and central nervous system- (CNS) targeted science. The company lists key differentiators, including: Approximately nine times higher bioavailability at peak plasma concentration versus naïve resveratrol No gastrointestinal (GI) side …United States · United States Read Article

Nimbus designing potential best-in-class small molecule medicines for difficult-to-drug targets - BioTuesdays

Open the article to view the coverage from biotuesdays.comUnited States · United States Read Article

Bryan Baum joins Senti’s BOD - BioTuesdays

Senti Bio (NASDAQ: SNTI) has announced the appointment of entrepreneurial leader and investor Bryan Baum to its board of directors (BOD). Mr. Baum is the co-founder and managing partner of K5 Global. His portfolio includes SpaceX, xAI, Anduril, Canva, Databricks, Grafana, OpenAI, and others. He has also founded and successfully exited multiple ventures. Timothy Lu, MD, PhD, co-founder and CEO of Senti, commented, “We are pleased to welcome Bryan…Maryland · Maryland Read Article

Ekso Bionics launches virtual eksoUniversity to support CE for PTs and PTAs - BioTuesdays

Ekso Bionics (NASDAQ: EKSO) has announced the launch of eksoUniversity, a new platform providing continuing education (CE) courses to physical therapists (PTs) and physical therapy assistants (PTAs) across the U.S. Most states require healthcare professionals to complete a predetermined number of continuing education units (CEUs) within each license renewal cycle. The goal of this requirement is to maintain competency in fields that are constant…Education · United States Read Article

Cognition’s positive data from Phase 2 study of zervimesine in DLB presented at AAIC - BioTuesdays

Cognition Therapeutics (NASDAQ: CGTX) has announced that James Edward Galvin, MD, MPH, will present results from the Phase 2 SHIMMER study of zervimesine (CT1812) in dementia with Lewy bodies (DLB) during an oral presentation at the Alzheimer’s Association International Conference (AAIC) on July 29, 2025, at 8:00 am ET. Dr. Galvin is director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine and wa…Dementia · Maryland Read Article

Revelation completes patient dosing in study of Gemini in CKC - BioTuesdays

Revelation Biosciences (NASDAQ: REVB) has announced the completion of dosing for its PRIME Phase 1b study of escalating doses of intravenously administered Gemini—a proprietary formulation of phosphorylated hexaacyl disaccharide—in patients with stage III and stage IV chronic kidney disease (CKC). According to Revelation, several study data sets are expected during Q3, 2025, including safety standards, changes in hematologic parameters, in vitro evaluation, and multiple biomarkers of activity. In a statement, James Rolke, CEO of Revelation, commented, “We thank our investigator and participants for the rapid completion of dosing. We are looking forward to sharing the study data shortly, and engaging the FDA to discuss future clinical development and approval pathways later this year.” The post Revelation completes patient dosing in study of Gemini in CKC appeared first on BioTuesdays.United States · United States Read Article

News from biotuesdays.com

News from biotuesdays.com

Information about biotuesdays.com

Media Bias Ratings

Factuality

Ownership

Top biotuesdays.com News

Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Cuprina Appoints Dr. Ronald Sherman, Leader in Maggot Debridement Therapy, as Medical and ...

Bioxytran disrupting infectious disease and inflammation with carbohydrate-based therapeutics - BioTuesdays

VVT Med completes RTO of V.V.T. Med and Exiteam Acquisition - BioTuesdays

Jupiter spotlights critical advancement of JOTROL v conventional resveratrol - BioTuesdays

Nimbus designing potential best-in-class small molecule medicines for difficult-to-drug targets - BioTuesdays

Bryan Baum joins Senti’s BOD - BioTuesdays

Ekso Bionics launches virtual eksoUniversity to support CE for PTs and PTAs - BioTuesdays

Cognition’s positive data from Phase 2 study of zervimesine in DLB presented at AAIC - BioTuesdays

Revelation completes patient dosing in study of Gemini in CKC - BioTuesdays

Similar News Topics

Topics Most Covered by biotuesdays.com

Sources Covering Similar Topics

Breaking News Topics Related to biotuesdays.com

Information about biotuesdays.com

Media Bias Ratings

Factuality

Ownership

Bioxytran disrupting infectious disease and inflammation with carbohydrate-based therapeutics - BioTuesdays

VVT Med completes RTO of V.V.T. Med and Exiteam Acquisition - BioTuesdays

Jupiter spotlights critical advancement of JOTROL v conventional resveratrol - BioTuesdays

Nimbus designing potential best-in-class small molecule medicines for difficult-to-drug targets - BioTuesdays

Bryan Baum joins Senti’s BOD - BioTuesdays

Ekso Bionics launches virtual eksoUniversity to support CE for PTs and PTAs - BioTuesdays

Cognition’s positive data from Phase 2 study of zervimesine in DLB presented at AAIC - BioTuesdays

Revelation completes patient dosing in study of Gemini in CKC - BioTuesdays